China Pharma Holdings (CPHI)
XASE:CPHI
Top Page
China Pharma Holdings
(NYSE MKT:CPHI)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.62
▼(-52.73% Downside)
Action:ReiteratedDate:04/02/26
The score is primarily weighed down by weak financial performance (persistent losses, poor margins, and historically negative cash flow) and a still-bearish technical trend (below key longer-term moving averages with negative MACD). Corporate events add a small offset through pipeline/IP expansion, but equity-funded deals and reverse-split authorization temper the benefit, while valuation metrics provided are not informative enough to improve the outlook.
Positive Factors
Pipeline / IP Expansion
Acquiring a Topiroxostat patent and related tech-transfer builds the company’s proprietary product pipeline and regulatory dossier capabilities. Patents and supporting R&D services can enable higher-margin specialty products, creating a durable growth vector if development and approvals proceed.
Negative Factors
Persistent Losses & Revenue Decline
Chronic revenue decline and sustained negative gross and net margins indicate structural demand, pricing, or cost issues. Persistent losses erode equity, constrain R&D and commercial investment, and make it harder to convert pipeline gains into profitable growth over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline / IP Expansion
Acquiring a Topiroxostat patent and related tech-transfer builds the company’s proprietary product pipeline and regulatory dossier capabilities. Patents and supporting R&D services can enable higher-margin specialty products, creating a durable growth vector if development and approvals proceed.
Read all positive factors
China Pharma Holdings (CPHI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.16M
Dividend YieldN/A
Average Volume (3M)41.02K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth-26.92%
EPS Growth69.90%
CountryUS
Employees224
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,022,002
10 Day Avg. Volume15,303
30 Day Avg. Volume41,022
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)<0.00001
P/FCF Ratio<0.01
Enterprise Value/Market Cap-51.18K
Enterprise Value/Revenue-0.04
Enterprise Value/Gross Profit1.23
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Pharma Holdings Business Overview & Revenue Model
Company Description
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of...
How the Company Makes Money
CPHI makes money primarily by selling pharmaceutical products. Its revenue model is based on (1) manufacturing finished dosage-form drugs and selling them into the domestic market through distributors and/or direct sales to hospitals, pharmacies, ...
China Pharma Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.14T | 4.53M | 7.01M | 8.10M | 9.64M |
| Gross Profit | -131.95B | -1.99M | -281.08K | -493.92K | 349.27K |
| EBITDA | -3.24T | -1.96M | 8.44K | -837.69K | 230.34K |
| Net Income | -3.19T | -4.74M | -3.08M | -3.97M | -3.40M |
Balance Sheet | |||||
| Total Assets | 31.00T | 14.89M | 16.47M | 17.78M | 22.65M |
| Cash, Cash Equivalents and Short-Term Investments | 345.11B | 626.88K | 1.42M | 2.03M | 4.86M |
| Total Debt | 183.18B | 3.59M | 4.63M | 8.76M | 12.49M |
| Total Liabilities | 8.26T | 7.14M | 9.01M | 13.49M | 16.63M |
| Stockholders Equity | 22.74T | 7.75M | 7.45M | 4.29M | 6.02M |
Cash Flow | |||||
| Free Cash Flow | 88.94B | -758.08K | -711.20K | -811.51K | -687.89K |
| Operating Cash Flow | 148.26B | -466.36K | -699.69K | -409.55K | -249.84K |
| Investing Cash Flow | -137.25B | -291.72K | -11.52K | -401.96K | -438.06K |
| Financing Cash Flow | -294.03B | 27.35K | 73.14K | -1.77M | 4.60M |
China Pharma Holdings Technical Analysis
Neutral
1.32
Price Trends
0.71
Negative
1.09
Negative
1.41
Negative
Market Momentum
-0.02
Negative
48.45
Neutral
79.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Neutral. The current price of 1.32 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.71, and below the 200-day MA of 1.41, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.45 is Neutral, neither overbought nor oversold. The STOCH value of 79.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPHI.
China Pharma Holdings Risk Analysis
China Pharma Holdings disclosed 55 risk factors in its most recent earnings report. China Pharma Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
China Pharma Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.78M | >-0.01 | 2.66% | ― | -27.81% | ― | |
45 Neutral | $3.16M | ― | -43.00% | ― | -26.92% | 69.90% | |
44 Neutral | $4.10M | -1.90 | -85.94% | ― | 25.02% | 55.11% | |
42 Neutral | $5.10M | -0.86 | -24.34% | ― | 13.24% | 98.80% |
* Healthcare Sector Average
CPHI
China Pharma Holdings
0.63
-0.67
-51.54%
SNOA
Sonoma Pharmaceuticals
2.37
0.46
24.08%
SISI
Shineco
0.30
-41.22
-99.28%
SBFM
Sunshine Biopharma
1.04
-0.45
-30.20%
UPC
Universe Pharmaceuticals
3.16
0.07
2.27%
China Pharma Holdings Corporate Events
Business Operations and StrategyM&A Transactions
China Pharma Expands R&D Portfolio With Patent Acquisition
Positive
Mar 3, 2026
On February 26, 2026, Hainan Helpson Medical Biotechnology, a subsidiary of China Pharma Holdings, entered into a technology transfer agreement to acquire full ownership of an invention patent covering Prinsepia Utilis Esterol sublingual tablets ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
China Pharma Acquires Topiroxostat Patent Via Equity Issuance
Positive
Feb 10, 2026
On February 5, 2026, Hainan Helpson Medical Biotechnology Co., Ltd., a wholly owned subsidiary of China Pharma Holdings, Inc., agreed to acquire full ownership of an invention patent covering a Topiroxostat nanoemulsion and its preparation method...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
China Pharma stockholders approve reverse split, governance changes
Positive
Jan 6, 2026
At its annual stockholders’ meeting held on December 30, 2025 for the fiscal year ended December 31, 2024, China Pharma Holdings, Inc. reported that approximately 69.71% of its outstanding common shares were represented, constituting a valid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.